MannKind | MNKD - Gross Profit On Sales


MannKind reported $78.31M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Adma Biologics USD 75.63M 8.4M Sep/2025
BioCryst Pharmaceuticals USD -88.88M 202.74M Dec/2024
Eli Lilly USD 14.59B 1.48B Sep/2025
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
Insmed USD 217.69M 106.25M Dec/2025
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
MacroGenics USD 61.25M 88.71M Sep/2025
MannKind USD 78.31M 76.21M Dec/2025
Merck USD 13.42B 431M Sep/2025
Minerva Neurosciences -4.27M 26.79M Dec/2024
Novavax USD 23.89M 239.21M Sep/2024
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Pfizer USD 3.54B 7.61B Sep/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Xencor USD 21M 22.61M Sep/2025